Financial reports
10-K
2023 FY
Annual report
8 Mar 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K
2022 FY
Annual report
10 Mar 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
10-K
2021 FY
Annual report
11 Mar 22
10-Q
2021 Q3
Quarterly report
5 Nov 21
Current reports
8-K
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
7 Mar 24
8-K
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
4 Mar 24
8-K
Results of Operations and Financial Condition
10 Jan 24
8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
8 Dec 23
8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
7 Dec 23
8-K
Other Events
4 Dec 23
8-K
Other Events
9 Nov 23
8-K
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments
1 Nov 23
8-K
EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team
16 Oct 23
8-K
Other Events
13 Sep 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
7 Dec 23
424B5
Prospectus supplement for primary offering
4 Dec 23
S-3
Shelf registration
20 Oct 23
S-8
Registration of securities for employees
20 Oct 23
S-8
Registration of securities for employees
9 Jan 23
424B5
Prospectus supplement for primary offering
18 Nov 21
FWP
Free writing prospectus
17 Nov 21
424B5
Prospectus supplement for primary offering
16 Nov 21
S-3
Shelf registration
6 Aug 21
S-8
Registration of securities for employees
6 Aug 21
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Sep 22
DEF 14A
Definitive proxy
28 Sep 22
PRE 14A
Preliminary proxy
16 Sep 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEF 14A
Definitive proxy
3 May 21
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEFA14A
Additional proxy soliciting materials
16 Oct 20
Other
EFFECT
Notice of effectiveness
31 Oct 23
CORRESP
Correspondence with SEC
26 Oct 23
UPLOAD
Letter from SEC
25 Oct 23
EFFECT
Notice of effectiveness
12 Aug 21
CORRESP
Correspondence with SEC
9 Aug 21
UPLOAD
Letter from SEC
9 Aug 21
EFFECT
Notice of effectiveness
10 May 21
CORRESP
Correspondence with SEC
5 May 21
SEC STAFF
SEC staff action: Order
5 Mar 21
UPLOAD
Letter from SEC
18 Feb 21
Ownership
4
Dario A. Paggiarino
2 Apr 24
4
Ramiro Ribeiro
4 Mar 24
3
Ramiro Ribeiro
4 Mar 24
4
Jay S. Duker
28 Feb 24
4
Jay S. Duker
22 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
4
Nancy Lurker
13 Feb 24
4
Dario A. Paggiarino
13 Feb 24
4
David Scott Jones
13 Feb 24